ICON plc is a global provider of clinical development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development. With headquarters in Dublin, Ireland, ICON currently, operates from 84 locations in 38 countries and has approximately 12,300 employees.
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also developing its digital health and enterprise services.
Barc Lab is a central laboratory with over 35 years of experience in clinical trials. Barc Lab comprises a global network of labs in the Americas, Europe, Africa, and the Asia Pacific region and acts as a genuine partner providing scientific expertise and a strong portfolio in the NASH field. OWL is a leading biotech company in the field of metabolomics developing and commercializing pioneering diagnostics products for high prevalence diseases, including NASH.
Continuum Clinical is a global clinical trial enrollment company. With over twenty-five years of experience, Continuum Clinical specializes in providing sponsors and CROs with patient recruitment and retention planning, study and site support, patient recruitment campaigns, patient advocacy and diversity & inclusion services, retention solutions, and reporting and analytics.
HepQuant-SHUNT, -STAT, and -FLOW are sensitive, reproducible, accurate, and minimally-invasive tests of global liver function and physiology. They target not only the liver but also the portal circulation and generate a Disease Severity Index (DSI), which ranges from 0 (healthy) to 50 (severe liver disease). DSI may be used for measuring severity of liver disease, tracking disease progression, and monitoring treatment effects. HepQuant’s services include study design, training, consultation, Test Kits, and Laboratory Analyses.
Kunming Biomed International (KBI) is a world leading CRO providing preclinical research services that specialized in nonhuman primates (NHPs). Led by an experienced international team, KBI has collaborated with over 18 large pharmas using translational NHP models for pharmacological efficacy and safety evaluations, including NASH/fibrosis, diabetes and diabetic complications (nephropathy, retinopathy), and cardiovascular diseases (dyslipidemia, heart failure), etc. KBI has state-of-the-art AAALAC accredited animal research facilities, and extensive colonies (>6000) of healthy and diseased models.
CrownBio’s metabolic disease portfolio is a unique continuum of translational platforms that enable our clients to take strategic go/no-go decisions as they progress their therapeutic candidates through various stages of drug development. Our clients engage with these translational platforms, which include rodent and non-human primates, (NHP) to model human liver disease pathologies and use them to predict human efficacy and safety of therapeutic candidates.
Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH, dyslipidemia, inflammation, diabetic nephropathy and cardiovascular complications.
For >15 years, we have been evaluating the efficacy of our clients' drugs using gold-standard and radio-tracer based experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners.
AES is the world’s largest site network, with 200 sites and 1,500+ employees. We provide customers with access to more than 100 million patients in key clinical development markets including the United States, Europe, Africa and Asia. Synexus has unmatched capacity to find the right patient for the right trial at the right time. Our global scale and world-class site network delivers unparalleled capability, data-driven site selection and activation, proven patient engagement and retention expertise.